Engineered Mesenchymal Stem Cell–Derived Extracellular Vesicles Reverse Endothelial–Mesenchymal Transition in Atherosclerosis
Journal of Extracellular Vesicles · 2025-06 · 14 (6)
DOI: 10.1002/jev2.70099 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Extracellular Vesicles, online erschienen am 23.06.2025. Verfasst von Zhuo Chen und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Rehabilitation Medicine, Key Laboratory of Physical Medicine and Precision Rehabilitation of Chongqing Municipal Health Commission, The…. Hauptthemen laut MEDLINE: Extracellular Vesicles, Mesenchymal Stem Cells, Atherosclerosis, Epithelial-Mesenchymal Transition. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: The National Natural Science Foundation of China, Chongqing Natural Science Foundation, Chongqing Medical Scientific Research Project.
Abstract (Originalsprache)
Endothelial–mesenchymal transition (EndMT) of vascular endothelial cells (VECs) plays a pivotal role in the progression of atherosclerosis (AS). The therapeutic potential of reversing EndMT holds promise for AS treatment. In this study, bone marrow mesenchymal stem cells (BMSCs)–derived extracellular vesicles (EVs) are engineered as nanostructured drug carriers with two functional modules, targeting module and functional protein module. In targeting module, to specifically target VECs, the cholesterol‐modified aptamers of VECs‐specific protein vascular endothelial growth factor (VEGF) are assembled to the engineered EVs. In functional protein module, engineered EVs are infected with recombinant silent information regulator 2–related enzyme 1 (SIRT1) adenoviruses, with the achievement of SIRT1 protein overexpression on the surface. Upon targeted aggregation around the mesenchymalized VECs, the engineered EVs are taken up by VECs and the loaded SIRT1 is released into VECs. Then, SIRT1 can effectively reverse VECs‐EndMT by activating nuclear factor‐erythroid 2–related factor 2 (Nrf2) and regulating oxidative stress response. The targeted efficacy for precision therapy in AS has been successfully demonstrated both in vitro and in vivo, by reversing EndMT and reducing inflammation in atherosclerotic plaques. This study provides a novel strategy for AS treatment and offers insights into the next generation of regenerative medicine technologies based on engineered EVs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Rehabilitation Medicine, Key Laboratory of Physical Medicine and Precision Rehabilitation of Chongqing Municipal Health Commission, The First Affiliated Hospital of Chongqing Medical University, Chongqing,…
- Department of Clinical Laboratory Medicine, Southwest Hospital, Army Medical University (Third Military Medical University), Chongqing, China.
- Army 953th Hospital (Shigatse Branch, Xinqiao Hospital), Third Military Medical University, Shigatse, China.
Förderung
- The National Natural Science Foundation of China
- Chongqing Natural Science Foundation
- Chongqing Medical Scientific Research Project
Zitieren
APA
Chen, Z., Chang, K., Yang, S., Deng, R., He, Y., Zhang, L., Chen, M., Bai, D., & Pi, Y. (2025). Engineered Mesenchymal Stem Cell–Derived Extracellular Vesicles Reverse Endothelial–Mesenchymal Transition in Atherosclerosis. Journal of Extracellular Vesicles, 14(6). https://doi.org/10.1002/jev2.70099
Vancouver
Chen Z, Chang K, Yang S, Deng R, He Y, Zhang L, et al. Engineered Mesenchymal Stem Cell–Derived Extracellular Vesicles Reverse Endothelial–Mesenchymal Transition in Atherosclerosis. Journal of Extracellular Vesicles. 2025;14(6). doi:10.1002/jev2.70099
BibTeX
@article{Chen2025,
author = {Chen, Zhuo and Chang, Kai and Yang, Sha and Deng, Ruijia and He, Yuan and Zhang, Ligai and Chen, Ming and Bai, Dingqun and Pi, Yan},
title = {Engineered Mesenchymal Stem Cell–Derived Extracellular Vesicles Reverse Endothelial–Mesenchymal Transition in Atherosclerosis},
journal = {Journal of Extracellular Vesicles},
year = {2025},
volume = {14},
number = {6},
doi = {10.1002/jev2.70099}
}
EUVIMED